Download MendeleyCrystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.
Mabanglo, M.F., Wilson, B., Noureldin, M., Kimani, S.W., Mamai, A., Krausser, C., Gonzalez-Alvarez, H., Srivastava, S., Mohammed, M., Hoffer, L., Chan, M., Avrumutsoae, J., Li, A.S.M., Hajian, T., Tucker, S., Green, S., Szewczyk, M., Barsyte-Lovejoy, D., Santhakumar, V., Ackloo, S., Loppnau, P., Li, Y., Seitova, A., Kiyota, T., Wang, J.G., Prive, G.G., Kuntz, D.A., Patel, B., Rathod, V., Vala, A., Rout, B., Aman, A., Poda, G., Uehling, D., Ramnauth, J., Halabelian, L., Marcellus, R., Al-Awar, R., Vedadi, M.(2024) Nat Commun 15: 10165-10165
- PubMed: 39580491 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s41467-024-54500-x
- Primary Citation Related Structures:
9B9H, 9B9T, 9B9W, 9BA2, 9DLW - PubMed Abstract:
Proteolysis-targeting chimeras (PROTACs) have been explored for the degradation of drug targets for more than two decades. However, only a handful of E3 ligase substrate receptors have been efficiently used. Downregulation and mutation of these receptors would reduce the effectiveness of such PROTACs. We recently developed potent ligands for DCAF1, a substrate receptor of EDVP and CUL4 E3 ligases. Here, we focus on DCAF1 toward the development of PROTACs for WDR5, a drug target in various cancers. We report four DCAF1-based PROTACs with endogenous and exogenous WDR5 degradation effects and high-resolution crystal structures of the ternary complexes of DCAF1-PROTAC-WDR5. The structures reveal detailed insights into the interaction of DCAF1 with various WDR5-PROTACs, indicating a significant role of DCAF1 loops in providing needed surface plasticity, and reflecting the mechanism by which DCAF1 functions as a substrate receptor for E3 ligases with diverse sets of substrates.
- Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.
Organizational Affiliation:
